Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Development of Blood Vessels01:07

Development of Blood Vessels

The development of the vascular system in a fetus is a complex and intricate process that begins as early as 15 to 16 days post-conception. This process starts outside the embryo, specifically in the mesoderm of the yolk sac, chorion, and connecting stalk. Approximately two days later, the formation of blood vessels occurs within the embryo itself.
The initial formation of this system is facilitated by the small amount of yolk present in the ovum and yolk sac. Blood vessels originate from...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The guide for the diagnosis and treatment of connective tissue disease-associated interstitial lung disease 2025.

Respiratory investigation·2026
Same author

Comparison of biomechanical assessment between upright and supine inspiratory-expiratory area-detector CT in progressive pulmonary fibrosis.

European radiology experimental·2026
Same author

A multicentre, prospective registry of patients with systemic sclerosis in Japan: baseline patient characteristics.

Modern rheumatology·2025
Same author

Immunosuppressive Therapy for Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases: Insights from Japanese Registry.

Advances in therapy·2025
Same author

Circulating microRNAs associated with tumour necrosis factor or fibloblast-like synoviocyte predict cartilage damage in early rheumatoid arthritis treated with methotrexate plus adalimumab: a subanalysis of the MIRACLE study.

Clinical and experimental rheumatology·2025
Same author

Characteristics of patients with systemic sclerosis with aspiration: A single-center study.

Journal of scleroderma and related disorders·2025

関連する実験動画

Updated: Jul 24, 2026

Generation and Grafting of Tissue-engineered Vessels in a Mouse Model
13:04

Generation and Grafting of Tissue-engineered Vessels in a Mouse Model

Published on: March 18, 2015

系統性硬化症における欠陥性血管新生

Masataka Kuwana1, Yuka Okazaki, Hidekata Yasuoka

  • 1Institute for Advanced Medical Research Keio University School of Medicine, Tokyo, Japan. kuwanam@sc.itc.keio.ac.jp

Lancet (London, England)
|August 18, 2004
PubMed
まとめ

系統性硬化症の患者は,循環する内皮前駆体が少なく,血管の修復を損なう. これは,欠陥血管新生が彼らの血管疾患に寄与し,潜在的な治療目標を提供することを示唆しています.

科学分野:

  • 心血管生物学 心血管生物学
  • 免疫学 免疫学とは
  • 再生医学は,再生医療である.

背景:

  • システミック硬化症 (SSc) は,毛細血管の密度低下と血管の消去を含む血管損傷によって特徴付けられます.
  • 血管新生,つまり血管の形成と修復は,循環する内皮前体 (CEP) に依存しています.
  • 血管新生障害は,SSc.で観察された血管病理の根底にある可能性があります.

研究 の 目的:

  • 血管新生が全身性硬化症の患者で障害があるかどうかを調査する.
  • SSc患者における循環内皮前駆体 (CEP) を,対照群と比較して定量化するために.
  • SSc.におけるCEPの差別化可能性を評価する.

主な方法:

  • 定量化されたCEP (CD34+,CD133+,VEGFR2+) は,SSc,リウマチ性関節炎,およびフローサイトメトリを用いた健康な対照群の周辺血液で測定された.
  • ELISAによる循環性血管新生因子の測定.
  • 評価されたCEPの差異化能力は,in-vitro成熟とフォン・ウィレブランド因子発現による.

主要な成果:

  • SSc患者は,関節リウマチ患者および健康な対照群と比較して,CEPの絶対値が著しく低いことを示した (p<0.0001).

さらに関連する動画

Generation of Human Blood Vessel Organoids from Pluripotent Stem Cells
09:46

Generation of Human Blood Vessel Organoids from Pluripotent Stem Cells

Published on: January 20, 2023

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases
04:59

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases

Published on: June 20, 2025

関連する実験動画

Last Updated: Jul 24, 2026

Generation and Grafting of Tissue-engineered Vessels in a Mouse Model
13:04

Generation and Grafting of Tissue-engineered Vessels in a Mouse Model

Published on: March 18, 2015

Generation of Human Blood Vessel Organoids from Pluripotent Stem Cells
09:46

Generation of Human Blood Vessel Organoids from Pluripotent Stem Cells

Published on: January 20, 2023

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases
04:59

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases

Published on: June 20, 2025

  • 逆説的に,循環する血管新生因子の濃度は,SSc患者で上昇しました.
  • 内皮細胞に微分化できるCEPの割合は,SSc患者で有意に減少した (p<0.0001).
  • 結論:

    • CEPの減少した数と差異化障害によって示される欠陥血管新生は,全身性硬化症で見られる血管病に寄与する可能性が高い.
    • 調節不良の血管新生は,がんや動脈硬化を含む他の血管疾患に関与する可能性があります.
    • CEPは,SScにおける不全性合併症の管理のための潜在的な治療目標です.